Loading...
•
Dec 31, 2025
Alkermes Q4 2025 Earnings Report
Alkermes reported fourth quarter 2025 results with solid proprietary product growth and GAAP net income of $49.3 million.
Key Takeaways
Alkermes generated Q4 2025 total revenues of 384547000, driven by total proprietary net sales of 315492000, and reported GAAP net income of 49341000 with diluted EPS of 0.29, supported by growth in LYBALVI.
Total revenues were 384547000 for the quarter.
Total proprietary net sales were 315492000, up from 307726000 in the prior year quarter.
GAAP net income was 49341000 with diluted EPS of 0.29.
Adjusted EBITDA was 100308000 for the quarter.
Revenue by Segment
Forward Guidance
For 2026, Alkermes expects total revenues between 1730000000 and 1840000000 and projects GAAP net loss driven by acquisition-related expenses, with adjusted EBITDA expected between 370000000 and 410000000.
Positive Outlook
- 2026 total revenue guidance of 1730000000 to 1840000000.
- Projected 2026 adjusted EBITDA between 370000000 and 410000000.
- Expected LYBALVI net sales of 380000000 to 400000000 in 2026.
- Expected VIVITROL net sales of 460000000 to 480000000 in 2026.
- Completion of Avadel acquisition strengthens sleep medicine portfolio.
Challenges Ahead
- Projected 2026 GAAP net loss of 115000000 to 135000000.
- Expected 2026 R&D expenses of 445000000 to 485000000.
- Expected 2026 SG&A expenses of 890000000 to 930000000.
- Expected amortization of intangible assets of 95000000 to 105000000.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...